Table 2.
Logistic regression of trial discontinuation and nonpublication
| Characteristic | Discontinued trials (n = 57) | Unpublished trials (n = 71) | ||
|---|---|---|---|---|
| No. (%) | AOR (95%CI) | No. (%) | AOR (95%CI) | |
| Intervention | ||||
| Pharmaceutical | 32 (22.54) | 1 [Ref] | 37 (26.06) | 1 [Ref] |
| Behavioral/dietary | 2 (1.41) | 1.07 (0.15–7.82) | 4 (2.82) | 2.8 (0.43–19.37) |
| Device | 13 (9.15) | 1.29 (0.52–3.18) | 18 (12.68) | 1.05 (0.92–5.64) |
| Procedure | 10 (7.04) | 1.5 (0.55–4.05) | 12 (8.45) | 0.78 (0.58–4.17) |
| Funding | ||||
| Hospital/university | 31 (21.83) | 1 [Ref] | 39 (27.46) | 1 [Ref] |
| Industry | 10 (7.04) | 0.96 (0.37–2.51) | 13 (9.15) | 0.48 (0.38–2.55) |
| Mixed | 15 (10.56) | 1.3 (0.53–3.2) | 14 (9.86) | 0.29 (0.24–1.55) |
| Other | 1 (0.7) | 0.14 (0.02–1.26) | 5 (3.52) | 0.57 (0.18–3.27) |
| Enrollment | ||||
| < 80 | 34 (59.6) | 1 [Ref] | 42 (59.2) | 1 [Ref] |
| ≥ 80 | 23 (40.4) | 0.42 (0.2–0.88) | 29 (40.8) | 0.12 (0.15–0.66) |
AOR adjusted odds ratio
Bold values indicate the Statistical significance set at P < 0.05